Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
anonusers Placed a 'Sell' Sentiment on UNVC1 day ago
anonusers Placed a 'Buy' Sentiment on HOME3 days ago
anonusers Placed a 'Sell' Sentiment on WBA3 days ago
russurban Placed a 'Buy' Sentiment on VXRT3 days ago
russurban Placed a 'Buy' Sentiment on OTLK3 days ago
russurban Followed OTLK3 days ago
stockarticles Placed a 'Buy' Sentiment on BB3 days ago
stockarticles Followed BB3 days ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT

Friday, September 29, 2017 Stock Pick

Stock Price: $3.75

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs.

CSBR has a technology dubbed "The Champions TumorGraft" that uniquely analyzes a patient's tumor based on its distinct set of molecular changes. This enables oncologists to create a personalized treatment for the patient and can be a powerful tool in extending a patient's life. Champions Oncology TumorGraft technology has engrafted 900+ tumors. Oncologists have been working directly with Champions Oncology. CSBR is proving out their TumorGraft technology.

The company also has research solutions, an area of their business that just received a $2 million contract with the National Cancer Institute. Not a bad accomplishment for a company worth just over $40 million right now. CSBR had revenue last year of $15.41 million, and reported record quarterly revenue of $5 million last quarter, a 37% Y-o-Y increase, on operating costs of $5.7 million. CSBR expects fiscal year 2018 revenue to come in at least 20% greater than 2017, which would put CSBR fiscal 2018 revenue at least at approximately $18.5 million.

CSBR's underlying fundamentals are improving and their foundation is not bad with the company getting closer to profitability. CSBR has no short term or long term debt as of last quarter on their balance sheet.

CSBR has seen an increase in volume the last two months, so it is slowly becoming discovered. CSBR has climbed from around $2.50 to as high as $4.37 since late-August. This trend can realistically continue as the company continues to progress and as investors continue to discover CSBR.

Speculative Score: 4

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

Untitled Document